GSK
811 hedge funds and large institutions have $10B invested in GSK in 2022 Q4 according to their latest regulatory filings, with 167 funds opening new positions, 234 increasing their positions, 275 reducing their positions, and 80 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
9% more funds holding
Funds holding: 741 → 811 (+70)
0.22% more ownership
Funds ownership: 6.57% → 6.78% (+0.22%)
15% less repeat investments, than reductions
Existing positions increased: 234 | Existing positions reduced: 275
Holders
811
Holding in Top 10
16
Calls
$420M
Puts
$157M
Top Buyers
| 1 | +$466M | |
| 2 | +$223M | |
| 3 | +$211M | |
| 4 |
Primecap Management
Pasadena,
California
|
+$117M |
| 5 |
Nomura Holdings
Tokyo,
Japan
|
+$73.2M |
Top Sellers
| 1 | -$326M | |
| 2 | -$231M | |
| 3 | -$106M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$97.6M |
| 5 |
Two Sigma Advisers
New York
|
-$81.5M |